Introduction
- Vedolizumab (VDZ) therapy can lead to histological and endoscopic improvement for patients with ulcerative colitis (UC), but its effects on the inflammatory microenvironment (IME) at the regional and cellular level have not been fully characterised.
- Uncovering biomarkers that can predict response to VDZ remains a critical step towards developing a precision medicine approach to treatment. This study utilised artificial intelligence (AI)–powered quantification of IME histology to identify biomarkers that predict endoscopic response in VDZ-treated patients with UC.
Conference
UEG Week
Partner
Takeda
Authors
- Magro et al.
